IMV Past Earnings Performance
Past criteria checks 0/6
IMV's earnings have been declining at an average annual rate of -3.8%, while the Biotechs industry saw earnings growing at 12.3% annually.
Key information
-3.8%
Earnings growth rate
7.7%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | n/a |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
IMV to cut ~33% workforce amid reorganization
Sep 15IMV receives Nasdaq non-compliance letter
Jul 08IMV names Jeremy Graff as chief scientific officer
Jun 09IMV's vaccine candidate potentially effective against COVID-19, shares up 16%
Dec 28IMV T cell therapy shows positive action in treatment-resistant ovarian cancer; shares up 5%
Dec 03IMV reports Q3 results
Nov 12Revenue & Expenses BreakdownBeta
How IMV makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 22 | 0 | -38 | 17 | 0 |
30 Sep 22 | 0 | -41 | 17 | 0 |
30 Jun 22 | 0 | -43 | 18 | 0 |
31 Mar 22 | 0 | -40 | 17 | 0 |
31 Dec 21 | 0 | -37 | 16 | 0 |
30 Sep 21 | 0 | -32 | 15 | 0 |
30 Jun 21 | 0 | -28 | 13 | 0 |
31 Mar 21 | 0 | -26 | 12 | 0 |
31 Dec 20 | 0 | -26 | 11 | 0 |
30 Sep 20 | 0 | -25 | 10 | 0 |
30 Jun 20 | 0 | -24 | 9 | 0 |
31 Mar 20 | 0 | -22 | 8 | 0 |
31 Dec 19 | 0 | -21 | 8 | 0 |
30 Sep 19 | 0 | -20 | 7 | 0 |
30 Jun 19 | 0 | -19 | 7 | 0 |
31 Mar 19 | 0 | -19 | 7 | 0 |
31 Dec 18 | 0 | -16 | 7 | 0 |
30 Sep 18 | 0 | -15 | 7 | 0 |
30 Jun 18 | 0 | -12 | 6 | 0 |
31 Mar 18 | 0 | -10 | 5 | 0 |
31 Dec 17 | 0 | -10 | 5 | 0 |
30 Sep 17 | 0 | -9 | 4 | 0 |
30 Jun 17 | 0 | -8 | 4 | -1 |
31 Mar 17 | 0 | -7 | 3 | -1 |
31 Dec 16 | 0 | -7 | 3 | 0 |
30 Sep 16 | 0 | -6 | 3 | 1 |
30 Jun 16 | 0 | -6 | 3 | 3 |
31 Mar 16 | 0 | -7 | 3 | 4 |
31 Dec 15 | 0 | -6 | 3 | 3 |
30 Sep 15 | 0 | -6 | 3 | 3 |
30 Jun 15 | 0 | -6 | 3 | 3 |
31 Mar 15 | 0 | -5 | 2 | 3 |
31 Dec 14 | 0 | -6 | 3 | 3 |
30 Sep 14 | 0 | -5 | 2 | 3 |
30 Jun 14 | 0 | -5 | 2 | 3 |
31 Mar 14 | 0 | -5 | 3 | 2 |
31 Dec 13 | 0 | -4 | 3 | 2 |
30 Sep 13 | 0 | -5 | 3 | 3 |
Quality Earnings: IMVI.Q is currently unprofitable.
Growing Profit Margin: IMVI.Q is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if IMVI.Q's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare IMVI.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMVI.Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: IMVI.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.